NCT06664411View on ClinicalTrials.gov

Pola-ZR2P in Previously Untreated DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy

Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy

Trial Locations (1)

100048

RECRUITING

Navy General Hospital, Beijing

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER